BioPharmSignal logoBioPharmSignal

Biotech News

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO)Allogene TherapeuticsEarnings

Conference Call and Webcast Scheduled for August 12, 2026 at 2:00 p.m. PT / 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T)

Related news

ALLOAllogene Therapeutics2026-05-06 12:30 EST

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-05-13 20:02 EST

Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

LEGNLegend Biotech Corporation2026-07-28 12:00 EST

Legend Biotech to Host Investor Conference Call on Second Quarter 2026 Results

LEGNLegend Biotech Corporation2026-03-10 11:00 EST

Legend Biotech Reports Fourth Quarter and Full Year 2025 Results and Recent Highlights

View all latest news

Allogene Therapeutics

Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Cema-cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for rapid administration without patient-specific manufacturing. First-Line LBCL Strategy The pivotal Phase 2...

Recent company news

ALLOAllogene Therapeutics2026-08-04 12:30 EST

Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update

ALLOAllogene Therapeutics2026-07-29 12:30 EST

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma

ALLOAllogene Therapeutics2026-07-15 12:30 EST

Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors

ALLOAllogene Therapeutics2026-05-28 21:02 EST

Allogene Therapeutics Announces Planned CEO Succession

ALLOAllogene Therapeutics2026-05-26 12:30 EST

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Stock data

Close
1.97 USD
Market cap
707.57M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States